恶性贫血(PA)被认为在西方国家非常普遍,但在中国很少报道。这项研究探讨了PA,一种自身免疫性疾病,在中国是钴胺(维生素B12)缺乏性贫血的罕见原因。
■收集了2014年7月至2021年12月期间90名钴胺缺乏引起的巨幼细胞性贫血(MA)患者的临床和血液学数据。通过抗内因子抗体(IFA)和抗壁细胞抗体(PCA)检测,PA与导致MA的钴胺素缺乏的其他原因不同。同时,纳入30名健康对照(HC)以估计IFA和PCA的阳性率。
■在30个HC中,只有一个IFA检测呈阳性,所有30人的PCA检测结果均为阴性。在90例钴胺缺乏引起的MA患者中,76.7%为IFA阳性,47.8%为PCA阳性;共有76例(84.4%)患者被诊断为PA。平均随访时间为41.0±16.3个月。在后续期间,在持续钴胺供应治疗的患者中没有复发的病例,而24.4%的患者因补充钴胺维持治疗中断而复发(中位复发时间为54.0±17.7个月).
■海南省钴胺缺乏引起的MA患者中PA的比例高于80%,这比预期的要普遍。因此,IFA筛查,PCA,内镜活检,对于所有钴胺缺乏引起的MA患者,建议与甲状腺相关的参数。此外,补充钴胺的维持治疗对PA患者很重要。
这项研究检查了恶性贫血(PA),一种由维生素B12缺乏引起的贫血,这在西方国家已经被广泛报道,但在中国却鲜为人知。这项研究的重点是确定PA是否也是海南这种缺乏的重要原因,中国。研究人员收集了由于缺乏维生素B12而患有巨幼细胞性贫血(一种血液疾病)的患者的数据,将其与健康个体进行比较,以了解PA的普遍程度。研究结果表明,研究的患者中有很高的百分比患有PA,远远高于预期。这表明PA在中国这个地区并不像以前认为的那样罕见。该研究还强调了维生素B12持续治疗以预防贫血复发的重要性。基于这些结果,研究人员建议,所有维生素B12缺乏的患者都应进行PA检测,并在诊断为PA后持续接受维生素B12补充剂以维持其健康.这种战略洞察力对中国的医疗从业者至关重要,可能为增强受此疾病折磨的个人的临床管理方案铺平道路。
UNASSIGNED: Pernicious anemia (PA) is believed to be highly prevalent in Western countries but has rarely been reported in
China. The study explores whether PA, an autoimmune disease, is an uncommon cause of cobalamin (vitamin B12) deficiency anemia in
China.
UNASSIGNED: Clinical and hematological data were collected from 90 cobalamin deficiency-caused megaloblastic anemia (MA) patients between July 2014 and December 2021. Through anti-intrinsic factor antibody (IFA) and anti-parietal cell antibody (PCA) testing, PA was distinguished from other causes of cobalamin deficiency leading to MA. Meanwhile, 30 healthy controls (HCs) were included to estimate the positive rates of IFA and PCA.
UNASSIGNED: Of the 30 HCs, only one tested positive for IFA, and all 30 tested negative for PCA. Among the 90 patients with cobalamin deficiency-caused MA, 76.7% were positive for IFA, and 47.8% were positive for PCA; a total of 76 patients (84.4%) were diagnosed with PA. The mean follow-up time was 41.0 ± 16.3 months. During the follow-up period, no case relapsed among the continuous cobalamin-supply treatment patients, while 24.4% of patients relapsed due to the interruption of maintenance cobalamin-supplement therapy (the median recurrence time was 54.0 ± 17.7 months).
UNASSIGNED: The proportion of PA in cobalamin deficiency-caused MA patients in Hainan province was higher than 80%, which was more common than expected. Therefore, screening for IFA, PCA, endoscopic biopsy, and thyroid-related parameters are recommended for all cobalamin deficiency-caused MA patients. Furthermore, maintenance cobalamin-supplement therapy is important for PA patients.
This research examines pernicious anemia (PA), a type of anemia caused by vitamin B12 deficiency, which has been widely reported in Western countries but is less known in China. The study focuses on determining if PA is also a significant cause of this deficiency in Hainan,
China. Researchers gathered data from patients with megaloblastic anemia (a blood disorder) due to lack of vitamin B12, comparing them with healthy individuals to see how common PA is. The findings reveal that a very high percentage of the patients studied have PA, much higher than expected. This suggests that PA is not as rare in this region of
China as previously thought. The study also highlights the importance of continuous treatment with vitamin B12 to prevent the recurrence of the anemia. Based on these results, the researchers recommend that all patients with vitamin B12 deficiency should be tested for PA and continuously receive vitamin B12 supplements to maintain their health once diagnosed with PA. This strategic insight is of paramount importance to medical practitioners in
China, potentially paving the way for enhanced clinical management protocols for individuals afflicted by this ailment.